Zevra Therapeutics
ZVRA
40 hedge funds and large institutions have $40.8M invested in Zevra Therapeutics in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
18% more funds holding
Funds holding: 34 → 40 (+6)
6% less capital invested
Capital invested by funds: $43.5M → $40.8M (-$2.71M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
+$2.24M |
| 2 |
Millennium Management
New York
|
+$828K |
| 3 |
Morgan Stanley
New York
|
+$699K |
| 4 |
Renaissance Technologies
New York
|
+$558K |
| 5 |
PVI
Pura Vida Investments
New York
|
+$366K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IG
ING Group
Amsterdam,
Netherlands
|
-$1.1M |
| 2 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$280K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$141K |
| 4 |
CW
CreativeOne Wealth
Overland Park,
Kansas
|
-$130K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$55.4K |
ZVRA Hedge Fund Activity: Q2 2018 in Review
40 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2018, worth a combined $40.8M — down 6.2% from $43.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ZVRA positions and 4 closed out — a net gain of 6 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Cowen Inc, opening a new position worth an estimated $2.24M. The largest seller was ING Group, exiting entirely with an estimated $1.1M sold.
- 40 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2018, up from 34 in Q1 2018.
- Funds reported $40.8M of Zevra Therapeutics stock for Q2 2018, down 6.2% quarter-over-quarter.
- 10 funds opened new Zevra Therapeutics positions in Q2 2018 and 4 closed out, a net change of +6 holders.
- The largest Zevra Therapeutics buyer in Q2 2018 was Cowen Inc, an estimated $2.24M added.
- The largest Zevra Therapeutics seller in Q2 2018 was ING Group, an estimated $1.1M sold.
Based on aggregated 13F filings for Q2 2018.